Totality of the evidence at work: The first US biosimilar

被引：34

作者：

Holzmann, J. ^{[1
]}

Balser, S. ^{[2
]}

Windisch, J. ^{[1
]}

机构：

[1] Sandoz Biopharmaceut, Biopharmaceut Dev, A-6250 Kundl, Austria

[2] HEXAL AG, Clin Dev Biopharmaceut, Oberhaching, Germany

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2016年 / 16卷 / 02期

关键词：

Biosimilar; filgrastim; filgrastim-sndz; G-CSF; Neupogen; neutropenia; Zarxio; FILGRASTIM; CHEMOTHERAPY; NEUTROPENIA;

D O I：

10.1517/14712598.2016.1128410

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

On March 6(th) 2015, the Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio) as the first biosimilar in the United States (US) for all indications of the reference product. Filgrastim-sndz is a biosimilar of Amgen's Neupogen and is mainly used to treat neutropenia in cancer patients receiving chemotherapy. This article presents a summary of the analytical and clinical studies submitted by Sandoz and describes how the information was integrated to provide the totality of the evidence' leading to the approval of the biosimilar.

引用

页码：137 / 142

页数：6

共 50 条

[41] NOVARTIS FILES FOR BIOSIMILAR IN US
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2014, 92 (31) : 19 - 19
[42] First insulin biosimilar
[J]. Nature Biotechnology, 2014, 32 (8) : 707 - 707
[43] US biosimilar pathway: New route to biosimilar biologic drugs
Berks, Andrew
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[44] Japan biosimilar first
不详
[J]. CHEMISTRY & INDUSTRY, 2009, (13) : 8 - 8
[45] AN OVERVIEW OF THE BIOSIMILAR MARKET IN THE US
Young, K. E.
Remuzat, C.
Urbinati, D.
Toumi, M.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A410 - A410
[46] Totality of evidence needed for nutrition recommendations
Arne Astrup
Jennie Brand-Miller
[J]. Nature Reviews Endocrinology, 2014, 10 : 310 - 310
[47] First US biosimilar edges towards market (vol 33, pg 222, 2015)
Senior, Melanie
[J]. NATURE BIOTECHNOLOGY, 2015, 33 (05) : 439 - 439
[48] Totality In Architecture. Reflections on aesthetics and the coexistence of things with the place producing in us an experience of totality
Gallardo Frias, Laura
[J]. PENSAMIENTO, 2017, 73 (277): : 923 - 942
[49] A REVIEW OF US BIOSIMILAR APPROVALS: WHAT EVIDENCE IS FDA REQUIRING, AND HOW ARE MANUFACTURERS RESPONDING?
Hung, A.
Mostovoy, L.
Vu, Q.
[J]. VALUE IN HEALTH, 2017, 20 (05) : A66 - A66
[50] GREEN LIGHT FOR US BIOSIMILAR DRUG
Schulz, William
[J]. CHEMICAL & ENGINEERING NEWS, 2015, 93 (30) : 12 - 12

← 1 2 3 4 5 →